All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Live Symposium

How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma

At the ESH 7th Translational Research Conference:

Multiple Myeloma

with Martin Kaiser, Mohamad Mohty, and Rakesh Popat

Saturday, October 5, 2024 | 09:10-10:10 CEST

Register now

This independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-06-21T09:13:21.000Z

Isa-VRd for transplant-ineligible patients with NDMM: Interim results from the IMROZ trial

Jun 21, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

The combination of bortezomib, lenalidomide, and dexamethasone (VRd) is considered the standard of care for patients with newly diagnosed (ND) multiple myeloma (MM).1,2 The phase III IMROZ trial (NCT03319667) is evaluating whether addition of isatuximab, an anti-CD38 monoclonal antibody, to the VRd regimen (Isa-VRd) improves outcomes for patients with NDMM who are ineligible for transplantation.1,2 Interim results from this trial were presented by Facon1 during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and have been published in The New England Journal of Medicine by Facon et al.2  

Key learnings:

The IMROZ study met its primary endpoint of PFS: median PFS was not reached at 54.34 months, and the 60-month PFS rate was 63.2% and 45.2%, in the Isa-VRd and VRd arms, respectively. 

After a median follow-up of 5 years, Isa-VRd was associated with a 40.4% reduction in the risk of progression or death vs VRd. 

Isa-VRd was also associated with a higher complete response (CR) rate (74.7% vs 64.1%), a higher measurable residual disease-negative (MRD) CR rate (55.5% vs 40.9; p = 0.003), and a higher rate of sustained MRD− for ≥12 months (46.8% vs 24.3%) when compared with VRd 

The improved efficacy with Isa-VRd, combined with a tolerable safety profile, suggests that Isa-VRd could be a new standard of care for transplant-ineligible patients with NDMM  


  1. Facon T. Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). Abstract #7500. Presented at: 2024 American Society of Clinical Oncology Annual Meeting; May 31 – Jun 4, 2024; Chicago, US.  
  2. Facon T, Dimopoulos MA, Leleu XP, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024. Online ahead of print. DOI: 10.1056/NEJMoa2400712 

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
39 votes - 30 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox